Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

GoodRx Holdings, Inc. GDRX

Healthcare — Health Information Services

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
9.77
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — — — — — 2 —
Insider Ownership
73.99%

Capital & Financial Ratios

Market Cap
1,150.00
Revenue
785.23
Net Income
16.25
Free Cash Flow
131.70
Net Debt
190.48
Current Ratio
1.38
Debt/Equity
0.75
P/E ratio
67.60
P/S ratio
1.46
P/B ratio
1.77
Past 5Y EPS Growth
(17.73%)
This Y EPS Growth
(13.09%)
Next Y EPS Growth
17.05%
Next 5Y EPS Growth
5.96%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 672.30 448.35 261.82 296.11
Receivables 143.61 145.93 235.75 182.14
Inventory — — — —
Other — 22.94 98.33 1,076.01
872.79 659.26 643.10 1,599.33
2023 2024 2025 Q'26
Payables 36.27 14.14 19.41 8.91
ST’ Debt 8.79 5.00 5.00 5.00
Other — 15.80 130.14 1,040.00
122.56 123.90 246.00 1,157.87
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡‡‡ ‡‡‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 194.01 200.41 — —
—
’25 202.97 203.07 196.03 194.79
796.85
’24 197.88 200.61 195.25 198.58
792.32
’23 183.99 189.68 179.96 196.64
750.27
’22 203.33 191.80 187.32 184.11
766.55
’21 160.43 176.64 195.10 213.26
745.42
’20 133.41 123.30 140.45 153.54
550.70
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 11.84 80.83 — —
—
’25 9.41 49.58 76.02 32.89
167.90
’24 42.59 9.70 86.86 44.74
183.89
’23 32.29 29.87 60.27 15.87
138.29
’22 30.12 51.05 33.73 31.88
146.78
’21 45.49 34.93 48.56 49.81
178.78
’20 45.59 38.23 32.67 14.85
131.34
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (9.81) 66.42 — —
—
’25 (12.46) 31.27 58.02 17.06
93.88
’24 21.97 (7.53) 71.00 28.10
113.55
’23 18.00 14.91 46.62 3.00
82.53
’22 17.70 37.32 19.96 16.59
91.57
’21 35.79 27.93 40.05 40.55
144.32
’20 42.19 33.32 14.97 5.04
95.52
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.00 0.02 — —
—
’25 0.03 0.04 0.00 0.02
0.09
’24 0.00 0.02 0.01 0.02
0.04
’23 (0.01) 0.14 (0.09) (0.06)
(0.02)
’22 0.03 0.00 (0.10) 0.00
(0.08)
’21 0.00 0.07 (0.04) (0.10)
(0.06)
’20 0.07 0.07 (0.21) (0.74)
(1.07)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.6
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 3.82 4.14 4.09 2.61 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 33.15 9.37 9.26 5.81 — — —
High Price
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 954 694 738 697 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.80 1.08 1.07 1.14 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 766.55 750.27 792.32 796.85 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 91.51% 91.08% 93.91% 92.77% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (23.23) (55.57) 31.46 56.54 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.03%) (7.41%) 3.97% 7.10% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.83) (8.87) 16.39 30.44 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 57.59 111.05 72.04 86.99 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.86 1.83 2.05 2.24 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.08) (0.02) 0.04 0.09 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.36 0.34 0.48 0.47 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.13) (0.14) (0.18) (0.21) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.22 0.20 0.29 0.26 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.97 1.86 1.88 1.73 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 412.86 410.32 385.74 356.33 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 93.00 30.11 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.54 3.07 2.26 1.21 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.39 3.03 2.48 1.57 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.41 3.05 2.32 1.50 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.16 27.75 16.18 12.70 — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 146.78 138.29 183.89 167.90 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (55.21) (55.77) (70.35) (74.02) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 91.57 82.53 113.55 93.88 ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 843.37 750.23 535.35 397.10 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 658.83 656.49 491.71 488.26 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (98.34) (15.81) 43.37 226.44 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 814.83 761.96 724.66 616.26 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.04%) (0.56%) 1.10% 2.18% ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.15% (2.26%) 5.36% 6.49% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.99%) (1.12%) 2.21% 4.54% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

GoodRx Holdings (GDRX) has endured a rollercoaster decade—from revolutionary drug pricing transparency platform to SPAC-fueled 2020 hype, brutal post-IPO crashes over 90% from peaks, and now glimmers of recovery with positive 2024 earnings and stabilizing revenue at $792 million (up 6% YoY). Efficiency is rebounding sharply: revenue per employee hit $1.08 million amid 23% headcount cuts, gross margins at 93.9%, and free cash flow per share surging 135% to $0.47, signaling scalability in a low-capex model battered by PBM competition and consumer pullbacks.

The profitability pivot is the game-changer: from deep losses and negative ROA to $16 million net income, 4% EBT margins, and projections tripling EPS to $0.25 by 2027 alongside ROE nearing 19%. Debt slashed 25% to $492 million fortifies the balance sheet, compressing valuations to dirt-cheap levels—PS at 2.3x, forward PE dropping to 11x by 2026—versus frothy 2021 multiples, with consensus targets implying 95% upside (bulls at 220%).

Yet caution lingers: absent insider buys, regulatory headwinds from drug pricing reforms, and Amazon/Walmart threats could derail the moat. Echoing post-hype telemedicine slumps, GDRX trades as value or trap—positioned for 2-3x potential if FCF execution holds, but risks demand vigilance. Dive deeper for the full dissection.

Read full commentary →

GoodRx Holdings, Inc. (GDRX) Latest News

News by impact score

Fine-tune

12 Aug

4 transcript www.fool.com, 7:03 PM
GoodRx (GDRX) released its Q2 2026 earnings call transcript covering quarterly financial results, performance metrics and forward outlook. Earnings call delivers key metrics and guidance that typically drive material shifts in valuation and investor positioning.

11 Aug

4 , 11:09 AM
GoodRx Holdings' Q2 results show Pharma Direct and subscription growth driving an upgraded outlook. Core segment growth triggers upgraded outlook and raises trajectory for GDRX performance.

10 Aug

4 , 4:58 PM
GoodRx subscription revenue surges 39% as company expands beyond prescriptions. 39% subscription revenue growth plus expansion signals major positive shift in performance and positioning.

6 Aug

4 transcript www.marketbeat.com, 2:04 PM
GoodRx Holdings Q2 earnings call highlighted revenue figures, user growth metrics, margin trends and strategic initiatives in prescription savings and telehealth. Q2 earnings details and forward guidance directly shape investor expectations for revenue trajectory and competitive positioning.

4 transcript app.moby.co, 8:30 AM
GoodRx Holdings, Inc. reported Q2 2026 financial results and business updates in its earnings call. Q2 2026 earnings and guidance directly affect GDRX valuation and investor outlook.

5 Aug

4 , 6:58 PM
GoodRx Holdings reported upbeat Q2 CY2026 results and its stock soared. Upbeat quarterly results triggered immediate stock gains reflecting stronger financial performance.

4 , 4:05 PM
GoodRx Holdings, Inc. reported its second quarter 2026 financial results. Quarterly earnings releases typically drive notable shifts in company valuation and investor outlook.

21 Jul

3 , 11:34 AM
GoodRx Holdings reports Q1 earnings, triggering analysis on whether to buy, sell or hold GDRX shares amid resulting market reaction and company outlook. Q1 earnings directly shape near-term financial views and investor positioning for GDRX without indicating major strategic shifts.

17 Jun

3 , 5:47 PM
GoodRx reported Q1 earnings and was compared against peer healthcare technology stocks. Q1 earnings data versus peers can moderately shift investor views on financial performance and positioning.

7 Jun

3 Insider Monkey, 1:59 PM
GoodRx Holdings strengthens recurring revenue base with Companion. Revenue base strengthening points to improved financial stability and growth outlook.

5 Jun

3 StockStory, 3:04 PM
GoodRx Holdings is singled out as a small-cap stock possessing competitive advantages, while two other unnamed small-caps are dismissed as unworthy of investor attention. Highlighting competitive advantages for GoodRx may lift near-term investor sentiment and valuation without altering core operations.

28 May

3 Simply Wall St., 2:06 AM
Shifting narratives for GoodRx are prompting analysts to revise views and adjust company valuation estimates. Evolving company narrative drives analyst revisions that moderately affect valuation perceptions.

27 May

3 Business Wire, 9:00 AM
GoodRx Holdings launches GoodRx Companion subscription service to reduce everyday healthcare costs. New subscription launch may moderately expand user base and revenue.

18 May

3 Bloomberg, 6:09 PM
Trump announces expansion of discount drug pricing program involving Mark Cuban, introducing new competitive pressures in prescription savings that could affect GoodRx Holdings market position and growth prospects. Trump-backed discount pricing expansion with Mark Cuban adds sector competition and regulatory shifts that moderately influence GoodRx trajectory.

16 May

3 StockStory, 6:04 PM
GoodRx Holdings addressed five key analyst questions during its Q1 earnings call covering revenue trends, user growth, cost controls, competitive pressures, and expansion initiatives. Earnings call analyst questions offer moderate insights into GoodRx strategy and outlook that can influence near-term investor sentiment.

15 May

3 Simply Wall St., 9:30 AM
GoodRx Holdings (NASDAQ:GDRX) reported soft earnings that appear stronger upon closer analysis, with underlying metrics exceeding initial impressions and signaling positive future potential. Earnings reframing positively influences financial perception and sentiment but remains balanced by broader market factors.

8 May

4 transcript www.fool.com, 11:30 AM
GoodRx (GDRX) released Q1 2026 earnings call transcript detailing financial results, guidance, and strategic updates. Q1 2026 earnings transcript discloses financial performance, forward guidance, and strategic initiatives that significantly shape investor expectations and stock trajectory.

7 May

4 www.marketbeat.com, 4:58 PM
GoodRx Holdings, Inc. released highlights from its Q1 earnings call, covering key financial metrics, operational updates, and forward guidance. Q1 earnings call highlights reveal financial results and guidance that significantly shape investor expectations and stock trajectory.

4 app.moby.co, 8:30 AM
GoodRx Holdings, Inc. (GDRX) released Q1 2026 earnings call summary covering financial performance, subscription growth, operational metrics, and forward guidance. Q1 2026 earnings disclosure reveals key financials and guidance shaping GDRX's market trajectory and investor sentiment.

6 May

4 , 7:30 PM
GoodRx (GDRX) Q1 earnings key metrics compared to estimates, highlighting performance in revenue, prescriptions, and profitability against analyst expectations. Q1 earnings metrics versus estimates signal major shifts in financial health and investor confidence for GDRX.

4 StockStory, 5:32 PM
GoodRx (NASDAQ:GDRX) beats Q1 CY2026 sales expectations. Beating quarterly sales expectations boosts financial performance and investor sentiment significantly.

4 Business Wire, 4:05 PM
GoodRx Holdings, Inc. (GDRX) reported first quarter 2026 results, highlighting key financial metrics, revenue growth, and future guidance. Quarterly earnings releases significantly impact GDRX's stock price, investor sentiment, and future performance expectations.

1 May

4 Business Wire, 8:10 AM
GoodRx Holdings, Inc. (GDRX) expands offerings to include Ozempic® pill for Type 2 diabetes patients. Adding high-demand Ozempic pill expands GoodRx's portfolio in booming diabetes treatment market, driving user growth and revenue.

15 Apr

4 , 9:00 AM
GoodRx now offers access to Wegovy HD at a self-pay price of $399 per month. Discounted access to high-demand Wegovy HD taps into booming GLP-1 weight loss market, driving customer growth and revenue potential.

14 Apr

4 Zacks, 8:55 AM
GoodRx Holdings, Inc. (GDRX) cuts revenue outlook, raising debate over temporary reset or structural concern amid operational challenges. Revenue outlook reduction signals major financial pressures likely to alter GDRX's trajectory and investor confidence.

9 Apr

4 Business Wire, 7:30 AM
GoodRx expands self-pay pricing access to Eli Lilly's new oral GLP-1 Foundayo™ and Zepbound® KwikPen® at more than 70,000 pharmacies nationwide. Expanding discounted access to high-demand GLP-1 weight loss drugs at 70,000 pharmacies strengthens GoodRx's position in a rapidly growing market segment.

24 Mar

4 Simply Wall St., 10:04 PM
Reset in expectations reframes GoodRx Holdings (GDRX) investment story, highlighting improved upside potential as lower forecasts align better with realistic growth amid consumer healthcare shifts. Reset expectations significantly boost GDRX investor sentiment and trajectory by aligning forecasts with achievable growth.

16 Mar

3 Zacks, 1:06 PM
Hims & Hers Health expands personalized digital healthcare access and services. HIMS expansion heightens competition in digital healthcare, pressuring GoodRx's positioning in prescription and telehealth markets.

11 Mar

4 Business Wire, 9:00 AM
GoodRx Holdings, Inc. (GDRX) partnered with Viatris to offer up to 85% savings on established brand medications through its prescription savings platform. Strategic partnership with Viatris expands GoodRx's discounted brand medication offerings, boosting user growth and revenue potential.

6 Mar

4 Business Wire, 9:00 AM
GoodRx Holdings, Inc. (GDRX) announces expansion of employer-sponsored access to Eli Lilly's Zepbound KwikPen, a tirzepatide injection for weight management, to increase affordability and utilization through its prescription savings platform. Expanding employer access to high-demand GLP-1 drug Zepbound drives prescription volume growth and revenue for GoodRx's core discount platform.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us